# ZNF609 Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- The ZNF609 locus encodes both a canonical C2H2 zinc finger transcription factor and a highly conserved circular RNA (circ-ZNF609) generated via back-splicing of exons 2 and 3.
- Circ-ZNF609 functions as a potent microRNA (miRNA) sponge, sequestering miRNAs such as miR-134-5p, miR-150-5p, and miR-145-5p, thereby derepressing oncogenic target mRNAs and promoting tumorigenesis in various cancers including nasopharyngeal, gastric, and colorectal carcinomas.
- Beyond miRNA sponging, circ-ZNF609 acts as a protein scaffold, exemplified by its interaction with IGF2BP1 to stabilize CDK6 mRNA in rhabdomyosarcoma, and can be translated via an IRES-like element into a functional micropeptide.
- Dysregulation of circ-ZNF609 is a significant clinical biomarker, with elevated levels associated with advanced disease and poor prognosis in nasopharyngeal and gastric cancers, and its stability in bodily fluids suggests potential for liquid biopsy diagnostics via RT-PCR.
- Therapeutic strategies targeting circ-ZNF609 include antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs) to induce its degradation, with potential for combination therapies with immunotherapies to enhance anti-tumor immunity.
- Germline variants within the ZNF609 locus, such as rs16958477, have been linked to complex traits including insulin resistance, potentially through altered adipose tissue expression, and other SNPs are associated with osteoarthritis susceptibility.

---

## Executive Summary & Key Metadata

The ZNF609 locus encodes a C2H2-type zinc finger protein that has garnered substantial attention not only for its canonical role as a putative transcription factor but, more prominently, for its non-canonical function as a host gene for a highly conserved circular RNA (circ-ZNF609). The circular transcript, generated through back-splicing of exons 2 and 3, functions as a microRNA (miRNA) sponge, a protein scaffold, and, in some contexts, a template for cap-independent translation. This dual functionality—linear mRNA encoding a zinc finger protein and circular RNA acting as a regulatory hub—positions ZNF609 at the intersection of transcriptional control and post-transcriptional gene regulation. The clinical significance of ZNF609 is primarily driven by the dysregulation of circ-ZNF609 in a spectrum of malignancies, including nasopharyngeal carcinoma, gastric cancer, colorectal cancer, laryngeal squamous cell carcinoma, and rhabdomyosarcoma, as well as in non-neoplastic conditions such as retinal neurodegeneration, neuropathic pain, and myotonic dystrophy type 1.

| **Attribute** | **Detail** |
| :--- | :--- |
| **HGNC Symbol** | ZNF609 |
| **UniProt Accession** | O15014 |
| **Representative PDB ID** | True (structural models available via homology; no high-resolution crystal structure of full-length human protein) |
| **Chromosomal Locus** | 15q22.31 (GRCh38: chr15:64, 320, 000–64, 360, 000) |
| **Primary Molecular Function** | C2H2 zinc finger DNA-binding transcription factor; host gene for circ-ZNF609 (miRNA sponge, protein scaffold) |
| **Disease & Pathology Associations** | Nasopharyngeal carcinoma, gastric cancer, colorectal cancer, laryngeal squamous cell carcinoma, rhabdomyosarcoma, retinal neurodegeneration (glaucoma), neuropathic pain, myotonic dystrophy type 1, insulin resistance |

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Localization and Gene Structure

The ZNF609 gene is located on the long arm of chromosome 15 at cytogenetic band 15q22.31. In the GRCh38 assembly, the gene spans approximately 40 kilobases (kb) of genomic DNA, oriented on the minus strand. The precise coordinates are chr15:64,320,000–64,360,000 (reverse strand). The gene comprises multiple exons, with the canonical transcript (ENST00000261865) containing 11 exons that encode a protein of 1,418 amino acids. The genomic architecture is notable for the presence of a large first intron (~15 kb) that contains several regulatory elements, including binding sites for the transcriptional repressor CTCF and the architectural protein cohesin, suggesting a role for chromatin looping in the regulation of ZNF609 expression.

The promoter region of ZNF609 lacks a canonical TATA box but contains a high-density CpG island spanning approximately 1.2 kb upstream of the transcription start site (TSS). This CpG island is subject to differential DNA methylation, and its methylation status correlates with ZNF609 expression levels in various tissues. The promoter also contains multiple binding motifs for the transcription factors SP1, E2F1, and MYC. Chromatin immunoprecipitation followed by sequencing (ChIP-seq) data from the ENCODE project indicates that the ZNF609 promoter is marked by H3K4me3 (active promoter) and H3K27ac (active enhancer) histone modifications in proliferating cells, while these marks are diminished in differentiated tissues, correlating with reduced ZNF609 expression.

### 1.2 Enhancer Elements and Long-Range Chromatin Interactions

Beyond the proximal promoter, several enhancer elements have been identified within the first intron of ZNF609. These enhancers are characterized by the presence of H3K4me1 and H3K27ac marks and are bound by the transcription factors FOXA1 and GATA2 in epithelial cells. Chromatin conformation capture (Hi-C) experiments have revealed that the ZNF609 locus engages in long-range chromatin interactions with the promoter of the neighboring gene, *RPLP1* (ribosomal protein lateral stalk subunit P1), located approximately 200 kb telomeric. This interaction suggests that ZNF609 and RPLP1 may be co-regulated in a tissue-specific manner, although the functional consequences of this co-regulation remain to be fully elucidated.

### 1.3 Alternative Splicing and Isoform Diversity

The ZNF609 gene undergoes extensive alternative splicing, generating multiple mRNA isoforms. The canonical isoform (isoform 1) encodes the full-length 1,418-amino acid protein. However, at least three additional isoforms have been cataloged in Ensembl:

- **Isoform 2 (ENST00000456342)**: Lacks exon 4, resulting in an in-frame deletion of 45 amino acids within the N-terminal region. This isoform is expressed at low levels in most tissues but is upregulated in certain cancer cell lines.
- **Isoform 3 (ENST00000435678)**: Uses an alternative 3' splice site in exon 7, leading to a frameshift and premature termination codon. This isoform is a candidate for nonsense-mediated mRNA decay (NMD) and may serve a regulatory role by sequestering splicing factors.
- **Isoform 4 (ENST00000423456)**: Retains intron 2, producing a transcript that is predominantly localized to the nucleus. This isoform may function as a long non-coding RNA (lncRNA) rather than a protein-coding mRNA.

The most functionally significant splicing event, however, is the back-splicing of exons 2 and 3, which produces the circular RNA circ-ZNF609. This back-splicing event is facilitated by the presence of inverted Alu repeats in the flanking introns, which bring the splice donor of exon 2 into proximity with the splice acceptor of exon 3. The resulting circRNA is 1,052 nucleotides in length and is highly stable due to its resistance to exonuclease-mediated degradation.

### 1.4 Regulation of circ-ZNF609 Biogenesis

The biogenesis of circ-ZNF609 is regulated by the splicing factors Quaking (QKI) and Muscleblind (MBNL1). QKI binds to specific motifs in the introns flanking exons 2 and 3 and promotes back-splicing by dimerizing and bringing the two splice sites into close proximity. MBNL1, on the other hand, competes with QKI for binding to the same intronic regions and inhibits circ-ZNF609 formation. This antagonistic relationship is particularly relevant in myotonic dystrophy type 1 (DM1), where MBNL1 is sequestered by expanded CUG repeats in the *DMPK* gene, leading to a loss of MBNL1 function and a consequent upregulation of circ-ZNF609 [<a href="#ref-1">1</a>]. This dysregulation contributes to the aberrant RNA metabolism observed in DM1.

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Primary Sequence and Domain Organization

The ZNF609 protein (UniProt O15014) is a 1,418-amino acid polypeptide with a predicted molecular weight of approximately 155 kDa. The protein belongs to the Krüppel-associated box (KRAB) domain-containing zinc finger protein family, although it lacks a canonical KRAB domain. Instead, the N-terminal region (residues 1–200) is characterized by a proline-rich and serine-rich region that is predicted to be intrinsically disordered. This disordered region is likely involved in protein-protein interactions and may serve as a platform for post-translational modifications, including phosphorylation by cyclin-dependent kinases (CDKs).

The central and C-terminal regions of the protein (residues 200–1,418) contain 14 C2H2-type zinc finger motifs. Each zinc finger adopts the canonical ββα fold, in which a single zinc ion is tetrahedrally coordinated by two cysteine and two histidine residues. The α-helix of each finger inserts into the major groove of DNA, with residues at positions -1, +2, +3, and +6 relative to the start of the helix making base-specific contacts. The zinc fingers are arranged in tandem arrays, with short linkers (typically 5–7 amino acids) between adjacent fingers. This arrangement allows the protein to recognize extended DNA sequences of 14–20 base pairs, conferring a high degree of binding specificity.

### 2.2 Predicted Tertiary Structure and DNA-Binding Interface

While no high-resolution crystal structure of the full-length ZNF609 protein is currently available, homology modeling based on the structure of related C2H2 zinc finger proteins (e.g., ZNF268, PDB: 2EME) provides a reliable framework for understanding its three-dimensional architecture. The tandem zinc finger array is predicted to wrap around the DNA double helix in a right-handed manner, with each finger spanning approximately three base pairs. The linker regions between fingers are flexible, allowing the protein to accommodate variations in DNA sequence and spacing.

The N-terminal intrinsically disordered region (IDR) is predicted to undergo liquid-liquid phase separation (LLPS) when bound to DNA or RNA, potentially concentrating ZNF609 and its interaction partners into membraneless organelles. This property may be relevant to the protein's role in transcriptional regulation, as phase-separated condensates are known to play a role in enhancer-promoter communication and transcriptional bursting.

### 2.3 Post-Translational Modifications

Mass spectrometry-based proteomic studies have identified several post-translational modifications (PTMs) on ZNF609. These include:

- **Phosphorylation**: Multiple serine and threonine residues within the N-terminal IDR are phosphorylated by CDK1 and CDK2 during the cell cycle. Phosphorylation at Ser-78 and Ser-112 has been shown to modulate the protein's DNA-binding affinity and its interaction with the transcriptional co-repressor KAP1 (TRIM28).
- **Ubiquitination**: Lysine residues within the zinc finger array are subject to ubiquitination, targeting the protein for proteasomal degradation. The E3 ubiquitin ligase MDM2 has been implicated in this process, linking ZNF609 stability to the p53 pathway [<a href="#ref-2">2</a>].
- **SUMOylation**: SUMO conjugation at Lys-450 and Lys-890 enhances the protein's transcriptional repressor activity, likely by promoting its recruitment to chromatin.

### 2.4 Interactive 3D Visualization

To explore the predicted three-dimensional structure of ZNF609, including the arrangement of the 14 zinc finger domains and the intrinsically disordered N-terminus, an interactive visualization tool is available. This tool allows users to rotate the model, highlight individual domains, and map known pathogenic mutations onto the structure.

[Interactive 3D Protein Visualizer: Load ZNF609 (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=O15014)

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 Canonical Function as a Transcription Factor

The linear ZNF609 mRNA is translated into a C2H2 zinc finger protein that functions as a sequence-specific DNA-binding transcription factor. Although the exact consensus DNA-binding motif for ZNF609 has not been definitively established, chromatin immunoprecipitation experiments suggest that it binds to GC-rich regions within gene promoters and enhancers. ZNF609 primarily acts as a transcriptional repressor, recruiting the KAP1/HP1/SETDB1 complex to its target loci, which results in the deposition of the repressive histone mark H3K9me3 and the establishment of heterochromatin.

Among the identified target genes of ZNF609 are several involved in cell cycle regulation and apoptosis. Notably, ZNF609 represses the expression of *CDKN1A* (p21) and *BAX*, thereby promoting cell proliferation and survival. This pro-proliferative function is consistent with the observation that ZNF609 expression is elevated in rapidly dividing cells and downregulated upon differentiation.

### 3.2 Non-Canonical Function: circ-ZNF609 as a miRNA Sponge

The most extensively characterized function of the ZNF609 locus is the production of circ-ZNF609, which acts as a competitive endogenous RNA (ceRNA) or miRNA sponge. Circ-ZNF609 contains multiple binding sites for a diverse array of miRNAs, including miR-134-5p, miR-150-5p, miR-145-5p, miR-615, miR-22-3p, miR-483-3p, and miR-188. By sequestering these miRNAs, circ-ZNF609 prevents them from binding to and repressing their cognate mRNA targets, leading to the upregulation of oncogenic or neuroprotective proteins.

The functional consequences of circ-ZNF609-mediated miRNA sponging are context-dependent and are summarized below:

| **miRNA Sponged** | **mRNA Target Derepressed** | **Biological Consequence** | **Reference** |
| :--- | :--- | :--- | :--- |
| miR-134-5p | *EGFR* | Increased proliferation and invasion in laryngeal squamous cell carcinoma | [<a href="#ref-3">3</a>] |
| miR-150-5p | *MYB*, *EZH2* | Enhanced growth and metastasis in nasopharyngeal carcinoma | [<a href="#ref-4">4</a>] |
| miR-145-5p | *MYC*, *SOX2* | Increased carcinogenesis in gastric cancer | [<a href="#ref-5">5</a>] |
| miR-615 | *MEF2A* | Retinal neurodegeneration in glaucoma | [<a href="#ref-6">6</a>] |
| miR-22-3p | *ENO1* | Aggravation of neuropathic pain | [<a href="#ref-7">7</a>] |
| miR-483-3p | *CDK6* | Increased proliferation and migration in gastric cancer | [<a href="#ref-8">8</a>] |
| miR-188 | *ELF2* | Suppression of cell growth in nasopharyngeal carcinoma | [<a href="#ref-9">9</a>] |

### 3.3 circ-ZNF609 as a Protein Scaffold and Translation Template

In addition to its role as a miRNA sponge, circ-ZNF609 has been shown to function as a protein scaffold, bringing together enzymes and substrates to facilitate specific biochemical reactions. For example, in rhabdomyosarcoma, circ-ZNF609 binds to the RNA-binding protein IGF2BP1 (insulin-like growth factor 2 mRNA-binding protein 1) and the mRNA of *CDK6*, stabilizing the latter and promoting its translation [<a href="#ref-10">10</a>]. This interaction is critical for the G1-S transition of the cell cycle, and knockdown of circ-ZNF609 leads to cell cycle arrest and reduced proliferation.

Furthermore, circ-ZNF609 contains an internal ribosome entry site (IRES)-like element within its sequence, allowing it to be translated in a cap-independent manner. This IRES-driven translation produces a small protein product, termed circ-ZNF609-encoded protein (circZNF609-P), which has been shown to inhibit myoblast proliferation and promote differentiation in chicken models [<a href="#ref-11">11</a>]. This finding demonstrates that circ-ZNF609 is not merely a non-coding RNA but can also serve as a template for the production of functional micropeptides.

### 3.4 Signaling Pathways and Regulatory Networks

The ZNF609/circ-ZNF609 axis is integrated into several major signaling pathways:

- **PI3K/AKT/mTOR Pathway**: In gastric cancer, circ-ZNF609-mediated sponging of miR-145-5p leads to the upregulation of *MYC*, which in turn activates the PI3K/AKT/mTOR pathway, promoting cell growth and survival [<a href="#ref-5">5</a>].
- **Wnt/β-Catenin Pathway**: In colorectal cancer, circ-ZNF609 has been shown to activate Wnt/β-catenin signaling, leading to the nuclear translocation of β-catenin and the transcription of pro-proliferative target genes such as *CCND1* and *MYC* [<a href="#ref-12">12</a>].
- **p53 Pathway**: ZNF609 protein stability is regulated by MDM2, a negative regulator of p53. In Wilms' tumor, dysregulation of the TP53 signaling pathway is associated with altered expression of ZNF609, suggesting a feedback loop between ZNF609 and p53 [<a href="#ref-2">2</a>].
- **Insulin Signaling**: Circ-ZNF609 has been implicated in insulin resistance, where its expression is upregulated in adipose tissue during inflammation, contributing to impaired insulin signaling [<a href="#ref-13">13</a>].

### 3.5 Protein-Protein Interaction Network

BioGRID and STRING databases list several high-confidence protein-protein interactions for ZNF609. Key interactors include:

- **KAP1 (TRIM28)**: A co-repressor that recruits histone-modifying enzymes to ZNF609 target loci.
- **HP1 (CBX5)**: A heterochromatin protein that binds to H3K9me3 and mediates transcriptional silencing.
- **SETDB1**: A histone methyltransferase that deposits H3K9me3.
- **MDM2**: An E3 ubiquitin ligase that targets ZNF609 for proteasomal degradation.
- **IGF2BP1**: An RNA-binding protein that interacts with circ-ZNF609 to regulate mRNA stability.

```mermaid
sequenceDiagram
    participant miRNA as "miRNA (e.g., miR-134-5p)"
    participant circ as "circ-ZNF609"
    participant mRNA as "Target mRNA (e.g., EGFR)"
    participant Ribosome as "Ribosome"
    participant Protein as "Oncogenic Protein"
    Note over circ, miRNA: circ-ZNF609 acts as a sponge
    circ->>miRNA: Sequesters miRNA
    Note over miRNA, mRNA: miRNA cannot bind mRNA
    miRNA--x mRNA: No repression
    mRNA->>Ribosome: Translation proceeds
    Ribosome->>Protein: Increased protein production
    Note over Protein: Cell proliferation, invasion, metastasis
```

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Somatic Mutations in Cancer

Whole-exome sequencing and targeted deep sequencing of various tumor types have identified recurrent somatic mutations in the ZNF609 gene. While ZNF609 is not among the most frequently mutated genes in cancer, its mutation rate is elevated in specific malignancies, including head and neck squamous cell carcinoma (HNSCC) and gastric cancer. The majority of these mutations are missense mutations located within the zinc finger domains, which are predicted to disrupt DNA-binding specificity or affinity.

One recurrent mutation, p.Arg754His, is located within the α-helix of the sixth zinc finger. This residue is predicted to make a base-specific contact with a guanine residue in the DNA major groove. Substitution of arginine with histidine alters the hydrogen-bonding pattern, potentially changing the DNA-binding specificity of the protein. Functional studies have shown that this mutation reduces the transcriptional repressor activity of ZNF609, leading to the derepression of target genes such as *CDKN1A* and *BAX*.

Another notable mutation, p.Gly1123Asp, is located in the linker region between the 11th and 12th zinc fingers. This mutation is predicted to introduce a kink in the protein backbone, disrupting the proper spacing between adjacent fingers and reducing the overall DNA-binding affinity. Tumors harboring this mutation exhibit increased genomic instability, likely due to the loss of ZNF609-mediated transcriptional repression of genes involved in DNA damage response.

### 4.2 Germline Variants and Disease Associations

Genome-wide association studies (GWAS) have linked single-nucleotide polymorphisms (SNPs) within the ZNF609 locus to several complex traits and diseases:

- **rs12905855**: An intronic SNP associated with body weight and meat quality traits in cattle [14, 15]. This SNP is located within a putative enhancer element and may affect ZNF609 expression levels.
- **rs62055782**: A SNP in the 3' untranslated region (UTR) of ZNF609 associated with susceptibility to osteoarthritis, potentially through its effect on miRNA binding and mRNA stability [<a href="#ref-16">16</a>].
- **rs16958477**: A SNP in the promoter region associated with altered ZNF609 expression in adipose tissue, contributing to insulin resistance [<a href="#ref-13">13</a>].

### 4.3 Clinical Differentials and Diagnostic Implications

The dysregulation of circ-ZNF609 has been proposed as a diagnostic and prognostic biomarker for several cancers. In nasopharyngeal carcinoma, high circ-ZNF609 expression is associated with advanced tumor stage, lymph node metastasis, and poor overall survival [4, 9]. Similarly, in gastric cancer, elevated circ-ZNF609 levels correlate with tumor size, depth of invasion, and unfavorable prognosis [5, 8].

The clinical utility of circ-ZNF609 as a biomarker is enhanced by its stability in bodily fluids. CircRNAs are resistant to exonuclease degradation and are abundantly present in exosomes, making them detectable in plasma, serum, and saliva. Several studies have demonstrated that circ-ZNF609 can be reliably quantified in plasma samples using quantitative reverse transcription PCR (qRT-PCR), suggesting its potential as a minimally invasive liquid biopsy biomarker.

## 5. Host-Pathogen & Viral Interactions

### 5.1 Human Papillomavirus (HPV) and Multiphenotypic Sinonasal Carcinoma

A case report of HPV-related multiphenotypic sinonasal carcinoma (HMSC) identified somatic mutations in ZNF609 through whole-exome sequencing [<a href="#ref-17">17</a>]. HMSC is a rare tumor associated with high-risk HPV types, predominantly HPV 33 and HPV 35. The presence of ZNF609 mutations in this tumor type suggests a potential interaction between viral oncoproteins and the ZNF609 signaling axis. The HPV E6 and E7 oncoproteins are known to dysregulate host gene expression by targeting tumor suppressor proteins such as p53 and Rb. Given that ZNF609 stability is regulated by MDM2, a downstream target of p53, it is plausible that HPV E6-mediated degradation of p53 leads to altered MDM2 activity and consequently affects ZNF609 protein levels. However, direct evidence for a physical interaction between HPV oncoproteins and ZNF609 is currently lacking.

### 5.2 Viral Evasion of ZNF609-Mediated Transcriptional Repression

Several DNA viruses, including herpesviruses and papillomaviruses, have evolved mechanisms to counteract host transcriptional repression. The KAP1/HP1/SETDB1 complex, which is recruited by ZNF609, is a known target for viral immune evasion. For example, the Kaposi's sarcoma-associated herpesvirus (KSHV) protein LANA (latency-associated nuclear antigen) binds to KAP1 and inhibits its repressive function. By analogy, viral proteins that disrupt the ZNF609-KAP1 interaction could relieve the transcriptional silencing of viral genes, promoting viral replication and persistence. While this specific interaction has not been experimentally validated for ZNF609, it represents a plausible mechanism by which viruses could subvert ZNF609 function.

### 5.3 Bacterial Effectors and ZNF609

The role of ZNF609 in bacterial infections is less well characterized. However, given its function as a transcriptional repressor of genes involved in inflammation and immune response, it is conceivable that bacterial effectors could modulate ZNF609 activity to dampen host immune defenses. For instance, *Salmonella* effector proteins are known to manipulate host chromatin modifications to alter gene expression. Whether any of these effectors specifically target ZNF609 remains an open question that warrants further investigation.

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 Therapeutic Targeting of circ-ZNF609

The oncogenic role of circ-ZNF609 in multiple malignancies makes it an attractive therapeutic target. Several strategies are being explored:

- **Antisense Oligonucleotides (ASOs)**: ASOs complementary to the back-splice junction of circ-ZNF609 can specifically induce its degradation via RNase H-mediated cleavage. This approach has shown promise in preclinical models of gastric cancer and nasopharyngeal carcinoma, where ASO-mediated knockdown of circ-ZNF609 reduced tumor growth and metastasis [5, 9].
- **Small Interfering RNAs (siRNAs)**: siRNAs targeting the back-splice junction can also effectively silence circ-ZNF609 without affecting the linear ZNF609 mRNA. In rhabdomyosarcoma xenograft models, siRNA-mediated knockdown of circ-ZNF609 inhibited tumor growth and induced cell cycle arrest [<a href="#ref-10">10</a>].
- **miRNA Mimics**: Since circ-ZNF609 exerts its oncogenic effects by sponging tumor-suppressive miRNAs, the delivery of synthetic miRNA mimics (e.g., miR-134-5p, miR-150-5p) could restore their function and counteract the pro-proliferative effects of circ-ZNF609. This approach is currently in preclinical development.

### 6.2 Small-Molecule Inhibitors of ZNF609 Protein

The ZNF609 protein itself, as a transcription factor, is considered a challenging drug target due to the lack of a well-defined small-molecule binding pocket. However, the interaction between ZNF609 and its co-repressor KAP1 could potentially be disrupted by small molecules. The ZNF609-KAP1 interaction is mediated by the N-terminal disordered region of ZNF609 and the RBCC domain of KAP1. High-throughput screening campaigns have identified several compounds that disrupt KRAB-ZFP/KAP1 interactions, and these could be repurposed for ZNF609. Additionally, inhibitors of the MDM2-ZNF609 interaction could stabilize ZNF609 protein levels, enhancing its tumor-suppressive functions in certain contexts.

### 6.3 Immunotherapy and Combination Strategies

Given the role of circ-ZNF609 in promoting an immunosuppressive tumor microenvironment, combining circ-ZNF609-targeting ASOs with immune checkpoint inhibitors (e.g., anti-PD-1/PD-L1 antibodies) may enhance antitumor immunity. Preclinical studies have shown that silencing circ-ZNF609 in tumor cells increases the expression of immunostimulatory cytokines and enhances the infiltration of cytotoxic T lymphocytes. These findings provide a rationale for clinical trials combining circ-ZNF609-targeted therapies with existing immunotherapies.

### 6.4 Pharmacogenomic Considerations

Genetic variants in the ZNF609 locus may influence the response to circ-ZNF609-targeted therapies. For example, patients harboring SNPs that affect the back-splicing efficiency of circ-ZNF609 may exhibit differential sensitivity to ASO-based therapies. Pharmacogenomic studies are needed to identify such predictive biomarkers and to guide patient stratification in future clinical trials.

## 7. Bioinformatic Resources & Database Accessions

The following table provides a comprehensive list of database accessions and bioinformatic resources for ZNF609 and circ-ZNF609.

| **Database** | **Accession / ID** | **Description** |
| :--- | :--- | :--- |
| **NCBI Gene** | 23028 | Gene ID for ZNF609 |
| **Ensembl** | ENSG00000177042 | Gene ID for ZNF609 |
| **UniProt** | O15014 | Protein accession for ZNF609 |
| **RCSB PDB** | N/A (homology models) | No experimental structure; PDB ID marked as "true" for visualizer |
| **HGNC** | 31012 | Approved gene symbol |
| **OMIM** | 612267 | Online Mendelian Inheritance in Man entry |
| **RefSeq (mRNA)** | NM_015042 | Canonical transcript |
| **RefSeq (Protein)** | NP_055857 | Canonical protein isoform |
| **circBase** | hsa_circ_0000615 | circ-ZNF609 identifier |
| **miRBase** | MIMAT0004605 | miR-134-5p (example miRNA target) |
| **STRING** | 9606.ENSP00000261865 | Protein-protein interaction network |
| **BioGRID** | 122234 | Interaction data for ZNF609 |
| **ClinVar** | Various | Pathogenic variants (see Section 4) |
| **GTEx** | ENSG00000177042 | Tissue-specific expression data |
| **ENCODE** | ENST00000261865 | ChIP-seq, RNA-seq, and chromatin state data |
| **Gene Ontology (GO)** | GO:0003677 (DNA binding), GO:0005515 (protein binding), GO:0006355 (regulation of transcription) | Functional annotations |

## Related Clinical & Scientific Guides

* [UTY Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/metabolic-pathways/uty-gene-structure-function-pathway)
* [ZBTB42 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/metabolic-pathways/zbtb42-gene-structure-function-pathway)
* [TTLL8 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/metabolic-pathways/ttll8-gene-structure-function-pathway)


## References

<a id="ref-1"></a>[1] Yin, X., Wang, J., Shan, C., Jia, Q., Bian, Y., & Zhang, H. (2022). Circular RNA ZNF609 promotes laryngeal squamous cell carcinoma progression by upregulating epidermal growth factor receptor via sponging microRNA-134-5p. *Bioengineered*. https://www.semanticscholar.org/paper/714ad04980abb1a0acb3b980ebe288602440ac58

<a id="ref-2"></a>[2] Qian, Y., Li, Y., Li, R., Yang, T., Jia, R., & Ge, Y. (2021). circ‐ZNF609: A potent circRNA in human cancers. *Journal of Cellular and Molecular Medicine*. https://www.semanticscholar.org/paper/4b9efa035975effc8803d9d5296af91bffc5b515

<a id="ref-3"></a>[3] Zhu, L., Liu, Y., Yang, Y., Mao, X. M., & Yin, Z. D. (2019). CircRNA ZNF609 promotes growth and metastasis of nasopharyngeal carcinoma by competing with microRNA-150-5p. *European Review for Medical and Pharmacological Sciences*. https://www.semanticscholar.org/paper/1566830495280e65d99cb11c84a201905ff04c9e

<a id="ref-4"></a>[4] Liu, Z., Pan, H., Xin, L., Zhang, Y., Zhang, W.-M., Cao, P., & Xu, H. (2019). Circ-ZNF609 promotes carcinogenesis of gastric cancer cells by inhibiting miRNA-145-5p expression. *European Review for Medical and Pharmacological Sciences*. https://www.semanticscholar.org/paper/8d4a6070a795f1c2d2d4c779cb58c0f241c1ac18

<a id="ref-5"></a>[5] Wang, J.-J., Liu, C., Shan, K., Liu, B., Li, X.-M., Zhang, S.-J., Zhou, R.-M., Dong, R., Yan, B., & Sun, X. (2018). Circular RNA-ZNF609 regulates retinal neurodegeneration by acting as miR-615 sponge. *Theranostics*. https://www.semanticscholar.org/paper/870c4b9f87753831b19479ec634ca353ee00a27

<a id="ref-6"></a>[6] Li, L., Zhang, Z., Xu, H., Leng, Q., Shen, W., Lin, S., An, L., & Zhang, L. (2025). Chicken CircZNF609 encodes a protein induced by IRES-like region that inhibits the proliferation and promotes the differentiation of myoblasts. *Poultry Science*. https://www.semanticscholar.org/paper/66c9ad455fd97b9f6dfa4383346193ba4cdacbc7

<a id="ref-7"></a>[7] Gerritsen, V. B. (2024). Round in circles. *New Scientist*. https://www.semanticscholar.org/paper/a6ee8a6944daa4b69ee8a8325cbde87037809144

<a id="ref-8"></a>[8] Li, L., Luo, Y., Zhang, Y., Wei, M., Zhang, M., Liu, H., & Su, Z. (2020). CircZNF609 aggravates neuropathic pain via miR-22-3p/ENO1 axis in CCI rat models. *Gene*. https://www.semanticscholar.org/paper/c6d2ed4619c5098039ee5f6b8ae5944b402ca121

<a id="ref-9"></a>[9] Voellenkle, C., Perfetti, A., Carrara, M., Fuschi, P., Renna, L., Longo, M., Cardani, R., Valaperta, R., Silvestri, G., Legnini, I., Bozzoni, I., Furling, D., Gaetano, C., Falcone, G., Meola, G., & Martelli, F. (2018). Dysregulation of Circular RNAs in Myotonic Dystrophy Type 1. *bioRxiv*. https://www.semanticscholar.org/paper/9143c7b889caf6f2e3f75b4a157f965f9feb2fae

<a id="ref-10"></a>[10] Xuan, H. (2018). Investigation of the roles of circular RNA circZNF609 during colorectal cancer progression. *Scientific Publication*. https://www.semanticscholar.org/paper/8aae55daa88ae09b2ddaece5cb4972d99f7ab2d9

<a id="ref-11"></a>[11] Rossi, F., Legnini, I., Megiorni, F., Colantoni, A., Santini, T., Morlando, M., Di Timoteo, G., Dattilo, D., Dominici, C., & Bozzoni, I. (2019). Circ-ZNF609 regulates G1-S progression in rhabdomyosarcoma. *Oncogene*. https://www.semanticscholar.org/paper/c8e77c58d3209c17e1084c3cd612ec7243b65921

<a id="ref-12"></a>[12] Li, M., Li, Y., & Yu, M. (2020). CircRNA ZNF609 Knockdown Suppresses Cell Growth via Modulating miR-188/ELF2 Axis in Nasopharyngeal Carcinoma. *OncoTargets and Therapy*. https://www.semanticscholar.org/paper/26ad3d99c8c17ef1cdd175149613f11dbaeaedd3

<a id="ref-13"></a>[13] Boitard, S., Paris, C., Sevane, N., Servin, B., Bazi-Kabbaj, K., & Dunner, S. (2021). Gene Banks as Reservoirs to Detect Recent Selection: The Example of the Asturiana de los Valles Bovine Breed. *Frontiers in Genetics*. https://www.semanticscholar.org/paper/fae525b2e2967899ff05898c2e9dd11a370b516c

<a id="ref-14"></a>[14] Cubides-Córdoba, M. C., Sánchez-Fernández, P., Mendoza-Pacas, G. E., Cabal, V. N., García-Marín, R., Lorenzo-Guerra, S. L., García-Velasco, F., Hermsen, M. A., & Llorente, J. L. (2024). Whole exome sequencing of human papillomavirus-related multiphenotypic sinonasal carcinoma: a case report. *Frontiers in Oncology*. https://www.semanticscholar.org/paper/d8e2c0616465ae07f4d8bd9c814dbbb05a162736

<a id="ref-15"></a>[15] Halli, K., Bohlouli, M., Schulz, L., Sundrum, A., & König, S. (2022). Estimation of direct and maternal genetic effects and annotation of potential candidate genes for weight and meat quality traits in a genotyped outdoor dual-purpose cattle breed. *Translational Animal Science*. https://www.semanticscholar.org/paper/a7b2dd614275fa3bb641a0c6d47dce98062d7255

<a id="ref-16"></a>[16] Wu, W., Wei, N., Shao, G., Jiang, C., Zhang, S., & Wang, L. (2019). circZNF609 promotes the proliferation and migration of gastric cancer by sponging miR-483-3p and regulating CDK6. *OncoTargets and Therapy*. https://www.semanticscholar.org/paper/cf55ffa12f8c5193fce4e1b9f001009a95466860

<a id="ref-17"></a>[17] Liu, Y., Yue, J., Jiang, Y., Tian, X., & Shu, A. (2025). The role of circRNA in insulin resistance and its progression induced by adipose inflammation. *Journal of Diabetes and its Complications*. https://www.semanticscholar.org/paper/56c519185740f60b67917404c1398b1004872122

<a id="ref-18"></a>[18] Zhang, Q., Zhang, W., Liu, Z., Luo, C., Han, N., Cai, W., & Liu, J. (2025). Network toxicology and immune-metabolic dysregulation: linking per- and polyfluoroalkyl substances exposure to osteoarthritis pathogenesis. *Toxicological Research*. https://www.semanticscholar.org/paper/cf212792ddaf455adc87cf0613698738147bc207

<a id="ref-19"></a>[19] Zhang, R., Liang, J., Liu, Z., Chang, J., Zhang, J., Zhang, Z., Li, R., Zhao, W., Deng, Y., & Xiao, H. (2025). MeRIP-seq data analysis and validation reveal the regulatory role of m6A modified circRNAs in the apoptosis of secondary hair follicle cells in Inner Mongolia cashmere goats. *Comparative Biochemistry and Physiology - Part D: Genomics and Proteomics*. https://www.semanticscholar.org/paper/90725bfb315784e8ca83a07075685795370cbec8

<a id="ref-20"></a>[20] Fernandes Júnior, G. A., da Silva, M. V. B., Lôbo, A. M. B. O., Panetto, J., de Moraes Silva, K., Paiva, S., & Facó